Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
Brief Summary: Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1
B: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User
C: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3

Answer: C